BioWorld

Feb. 8, 2008

View Archived Issues

BioNumerik Starts Phase III with Improved Chemo Drug

BioNumerik Pharmaceuticals Inc. started a pivotal Phase III trial comparing Karenitecin (BNP1350) with GlaxoSmithKline plc's Hycamtin (topotecan) in relapsed ovarian cancer. (BioWorld Today) Read More

BioVascular Gets $10.9M to Boost Vascular Compounds

Read More

New Research Implicates Lipid Metabolites in Insulin Resistance

Read More

Chelsea Begins Dosing in Droxidopa Pivotal Trial

Read More

Other News To Note

Read More

Clinic Roundup

Read More